Find in Library

The emergence of azole resistant <i>Aspergillus</i> spp., especially <i>Aspergillus fumigatus</i>, has been described in several countries around the world with varying prevalence depending on the country. To our knowledge, azole resistance in <i>Aspergillus</i> spp. has not been reported in the West Indies yet. In this study, we investigated the antifungal susceptibility of clinical and environmental isolates of <i>Aspergillus</i> spp. from Martinique, and the potential resistance mechanisms associated with mutations in <i>cyp51A </i>gene. Overall, 208 <i>Aspergillus</i> isolates were recovered from clinical samples (<i>n </i>= 45) and environmental soil samples (<i>n </i>= 163). They were screened for resistance to azole drugs using selective culture media. The Minimum Inhibitory Concentrations (MIC) towards voriconazole, itraconazole, posaconazole and isavuconazole, as shown by the resistant isolates, were determined using the European Committee on Antimicrobial Susceptibility Testing (EUCAST) microdilution broth method. Eight isolates (<i>A. fumigatus</i>, <i>n </i>= 6 and <i>A. terreus</i>, <i>n </i>= 2) had high MIC for at least one azole drug. The sequencing of <i>cyp51A</i> gene revealed the mutations G54R and TR34/L98H in two <i>A. fumigatus </i>clinical isolates. Our study showed for the first time the presence of azole resistance in <i>A. fumigatus</i> and <i>A. terreus</i> isolates in the French West Indies.